A novel class of NO-donating protoberberine derivatives were synthesized and initially evaluated for their anti-hepatocellular carcinoma activities. Most of the compounds exhibited more potent activity against HepG2 cells than parent compounds berberine and palmatine. In particular, compound 15a exerted the strongest activity with an IC50 value of 1.36 μM. Moreover, most compounds released moderate
合成了一类新的NO供体小to碱衍
生物,并初步评估了它们的抗肝细胞癌活性。与母体化合物小ber碱和棕榈碱相比,大多数化合物对HepG2细胞表现出更强的活性。特别地,化合物15a发挥最强的活性,IC 50值为1.36μM。此外,大多数化合物在体外释放中等
水平的NO,NO清除剂显着减弱了15a在HepG2细胞中的抗肿瘤活性。有趣的是,化合物15a显示出广谱抗肿瘤功效,并在肿瘤细胞(HepG2,
SMMC-7721,HCT-116,HL-60)和正常肝LO-2细胞之间具有良好的选择性。机制研究表明,15a阻断了细胞周期的G2期,并通过线粒体去极化诱导了HepG2细胞的凋亡。此外,在H22肝癌异种移植小鼠模型中,15a抑制了肿瘤生长62.5%(w / w),这显着优于母体化合物palmatine(41.6%,w / w)。总的来说,当前的研究可能为发现新型
抗肿瘤药物提供一种新方法。